Clal Insurance Enterprises Holdings Ltd Buys 77,970 Shares of Johnson & Johnson $JNJ

Key Points

• Clal Insurance increased its Johnson & Johnson stake by 51.9% in the second quarter, adding 77,970 shares to own 228,108 shares valued at approximately $57.9 million. Institutional investors collectively own 69.55% of JNJ.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $272.83; UBS initiated coverage with a $320 target. JNJ recently reported better-than-expected quarterly earnings and revenue growth of 6.6% year over year.
• Despite strong performance and a 64-year dividend-growth record, valuation and risk concerns remain following a roughly 60% one-year rally. Recent insider selling, lower EPS expectations, and unresolved talc litigation could weigh on investor sentiment.

Clal Insurance Enterprises Holdings Ltd increased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 51.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 228,108 shares of the company's stock after acquiring an additional 77,970 shares during the quarter. Clal Insurance Enterprises Holdings Ltd's holdings in Johnson & Johnson were worth $57,933,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Johnson & Johnson by 7.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 307,423 shares of the company's stock valued at $78,076,000 after acquiring an additional 21,189 shares during the last quarter. Capital Square LLC raised its stake in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Capital Square LLC now owns 7,530 shares of the company's stock valued at $1,935,000 after purchasing an additional 117 shares during the period. Mission Financial Group LLC bought a new stake in shares of Johnson & Johnson in the second quarter valued at about $615,000. Elefante Mark B boosted its position in shares of Johnson & Johnson by 9.8% during the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after buying an additional 2,563 shares during the period. Finally, LM Advisors LLC grew its holdings in shares of Johnson & Johnson by 309.2% during the second quarter. LM Advisors LLC now owns 9,022 shares of the company's stock worth $2,291,000 after buying an additional 6,817 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst sentiment remains supportive. JNJ received an upgrade that helped it reach a new 12-month high, while the broader analyst view is rated “Moderate Buy.” UBS also began coverage, potentially increasing institutional attention. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade Johnson & Johnson Receives Average Rating of Moderate Buy
• Positive Sentiment: Johnson & Johnson’s 64-year record of dividend growth remains a key support for income-oriented investors. Strong profitability and the company’s diversified healthcare portfolio help sustain the dividend despite competitive pressure on a major drug. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Neutral Sentiment: Management will discuss the business at the Deutsche Bank Healthcare Summit on September 17. The event could provide updates on pharmaceuticals, litigation and forward guidance, but it is not itself a change to earnings expectations. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: Profit-taking and valuation risk are elevated after JNJ gained about 60% over the past year versus roughly 21% for the S&P 500. Analysts question whether the current price already discounts growth above management’s near-term outlook. Was JNJ Stock Rally Actually Its Own? Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
• Negative Sentiment: An executive vice president sold 33,597 shares worth approximately $9.2 million, reducing his holdings by 56.9%. The sale may reinforce short-term concerns about insider conviction, although it does not change JNJ’s fundamentals. SEC insider transaction filing
• Negative Sentiment: An analyst lowered the FY2026 EPS forecast, adding pressure to expectations. Talc litigation also remains unresolved despite a proposed path toward settlement, while the Louisiana verdict continues to focus attention on legal liability and potential costs. Johnson & Johnson dividend and competition analysis

Insider Activity

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 97,569 shares of company stock worth $25,476,044. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on JNJ shares. Leerink Partners raised Johnson & Johnson from a "market perform" rating to an "outperform" rating and set a $265.00 target price on the stock in a research report on Wednesday, May 13th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. UBS Group initiated coverage on shares of Johnson & Johnson in a report on Wednesday. They issued a "buy" rating and a $320.00 price objective on the stock. Morgan Stanley increased their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a report on Thursday, July 16th. Finally, Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $272.83.

Johnson & Johnson Stock Down 1.2%

JNJ stock opened at $275.12 on Friday. The business's 50 day simple moving average is $261.98 and its 200 day simple moving average is $245.07. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $663.01 billion, a PE ratio of 31.88, a PEG ratio of 2.66 and a beta of 0.24. Johnson & Johnson has a 1-year low of $173.33 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the previous year, the firm posted $2.77 EPS. Johnson & Johnson's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's payout ratio is 62.11%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.